a role for the host dna damage response in hepatitis b virus cccdna formation—and beyond?

Tiklamalar: 200
ID: 194510
2017
Makale Kalitesi ve Performans Metrikleri
Genel Kalite Improving Quality
0.0 /100
Etkilesim verilerini yapay zeka tabanli akademik kalite degerlendirmesiyle birlestirir
Yapay Zeka Kalite Degerlendirmesi
Analiz edilmedi
Ozet
Chronic hepatitis B virus (HBV) infection puts more than 250 million people at a greatly increased risk to develop end-stage liver disease. Like all hepadnaviruses, HBV replicates via protein-primed reverse transcription of a pregenomic (pg) RNA, yielding an unusually structured, viral polymerase-linked relaxed-circular (RC) DNA as genome in infectious particles. Upon infection, RC-DNA is converted into nuclear covalently closed circular (ccc) DNA. Associating with cellular proteins into an episomal minichromosome, cccDNA acts as template for new viral RNAs, ensuring formation of progeny virions. Hence, cccDNA represents the viral persistence reservoir that is not directly targeted by current anti-HBV therapeutics. Eliminating cccDNA will thus be at the heart of a cure for chronic hepatitis B. The low production of HBV cccDNA in most experimental models and the associated problems in reliable cccDNA quantitation have long hampered a deeper understanding of cccDNA molecular biology. Recent advancements including cccDNA-dependent cell culture systems have begun to identify select host DNA repair enzymes that HBV usurps for RC-DNA to cccDNA conversion. While this list is bound to grow, it may represent just one facet of a broader interaction with the cellular DNA damage response (DDR), a network of pathways that sense and repair aberrant DNA structures and in the process profoundly affect the cell cycle, up to inducing cell death if repair fails. Given the divergent interactions between other viruses and the DDR it will be intriguing to see how HBV copes with this multipronged host system.
Referans Anahtari
schreiner2017virusesa Kullanarak makale yazarken otomatik alinti icin bu anahtari kullanin SciMatic Makale Yoneticisi veya Tez Yoneticisi
Yazarlar ;Sabrina Schreiner;Michael Nassal
Dergi International journal of pharmaceutics
Yil 2017
DOI
10.3390/v9050125
URL
Anahtar Kelimeler

Atiflar

Atif bulunamadi. Atif eklemek icin yoneticiyle iletisime gecin: info@scimatic.org

Henuz yorum yok. Bu makaleye ilk yorumu siz yapin.